Discover and read the best of Twitter Threads about #cancermoonshot
Most recents (6)
💉💉 I'm A Believer 💉💉
I thought love was only true in fairytales...
I thought love was only true in fairytales...
I believe this virus is scary. >
I believe the 💉s help prevent against serious illness & death. >
$NWBO @DCarnival46
#CancerMoonshot today will not only be about glioblastoma, but about the horrible DIPG (diffuse intrinsic pontine glioma) occuring in children and young adults.
You know who got their PIP plan approved last year by the MHRA in the UK?
#CancerMoonshot today will not only be about glioblastoma, but about the horrible DIPG (diffuse intrinsic pontine glioma) occuring in children and young adults.
You know who got their PIP plan approved last year by the MHRA in the UK?
You know who ANNOUNCED a new center of cancer excellence in Sutton in the UK two months ago, 130 miles from Sawston, focusing on DIPG?
You know who donated 2.5 million pounds to the center and that Hugh Adams works for them and have helped NWBO meeting british politicians and he wrote the "Pathway to a Cure" report, where politicians urges MHRA and NICE to get DCVax-L to patients?
1. ENTER #mRNAvaccines for #pancreaticcancer! Long-term #PDAC survivor story PART3.
"Do #PDACs REALLY have vaccine neoantigens (NAs)"? (aren’t they lowly mutated?)
If each patient = own NAs, how do you vaccinate?
Maybe mRNA? But how?
@Nature nature.com/articles/s4158…
👇🏽 [1/32]
"Do #PDACs REALLY have vaccine neoantigens (NAs)"? (aren’t they lowly mutated?)
If each patient = own NAs, how do you vaccinate?
Maybe mRNA? But how?
@Nature nature.com/articles/s4158…
👇🏽 [1/32]
2. In 2017, we reported in @Nature here -> nature.com/articles/natur… -> that primary tumors of long-term survivors of #PDAC had ~12x more activated CD8 T cells vs. short-term survivors
AND
despite #PDAC’s few mutations, mutation-derived NAs may still be T cell antigens in #PDAC.
AND
despite #PDAC’s few mutations, mutation-derived NAs may still be T cell antigens in #PDAC.
3. Now, prevailing belief ->#PDAC = few mutations = fewer mutation-derived NAs = NAs unlikely #PDAC T cell antigens.
BUT...our #NeoantigenQualityModel(estimates the ~1-2% of immunogenic NAs)
found that long term #PDACsurvivors ∝ more “high quality” NAs ∝longer survival.
BUT...our #NeoantigenQualityModel(estimates the ~1-2% of immunogenic NAs)
found that long term #PDACsurvivors ∝ more “high quality” NAs ∝longer survival.
Today, FDA approved Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2-low breast cancer, a newly defined subset of HER2-negative breast cancer. This is the first drug approved to treat this subtype. thread 1/3
#bcsm
fda.gov/news-events/pr…
#bcsm
fda.gov/news-events/pr…
About 80-85% of breast cancer diagnosed annually in the US were considered HER2-negative (including HR+ and triple negative breast cancer). Now, about 60% of patients previously considered HER2-negative can be considered HER2-low (IHC 1+ or IHC 2+/ISH‑) 🧵 2/3
#bcsm
#bcsm
Efficacy was based on DESTINYBreast04, a randomized clinical trial enrolling 557 patients with unresectable or metastatic HER2-low breast cancer. FDA approved this application about 4 months ahead of the PDUFA date.
🧵 3/3
#bcsm
🧵 3/3
#bcsm
In a recent lung cancer pilot study, we identified and quantified a record number of 13,187 protein groups with our next-generation single-shot proteomics technology HRM.
This was achieved using FAIMS-DIA with highest resolution chromatography and FAIMS Exploris 480. (1/n)
This was achieved using FAIMS-DIA with highest resolution chromatography and FAIMS Exploris 480. (1/n)
The depth of analysis was superior to the one achieved in the Deep Human Proteome Atlas (deep fractionated tissue with multiple MS acquisitions, Wang et al., 2019, Mol Syst Biol).
Comprehensively, we could identify 414 oncogenes, 392 transcription factors, 837 plasma membrane proteins (25 GPCR), and 316 kinases covering a dynamic range of 10. In addition, 0.25 Mio peptides (including modifications) were measured in totality.
A thread on our recent analysis of WES, RNAseq, and clinical predictors of response to PD-1 ICB in metastatic melanoma patients led by @vanallenlab, Dirk Schadendorf, and Bastian Schilling with many others!
@NatureMedicine @DanaFarber @broadinstitute
nature.com/articles/s4159…
@NatureMedicine @DanaFarber @broadinstitute
nature.com/articles/s4159…
@VanAllenLab @NatureMedicine @DanaFarber @broadinstitute Our cohort was 144 metastatic melanoma patients who received PD-1 ICB. Overall response rate (CR or PR) was 38%; and subtypes were 86% cutaneous or occult melanoma, 7% acral, and 7% mucosal. Median follow-up was 30 months. 39% had BRAF mutations, 30% NRAS, and 17% NF1. [2/n]
@VanAllenLab @NatureMedicine @DanaFarber @broadinstitute TMB was higher in responders vs. non-responders overall, as seen previously, but the effect is confounded by melanoma subtype; mucosal and acral melanomas have lower TMB and response rates. Stratified by subtype, the difference in TMB is no longer statistically significant. [3/n]
